Virtue® SAB

The First-In-Class Sirolimus AngioInfusionTM Balloon for the Treatment of Artery Disease

  • Patented, first-in-class device that delivers sirolimus, the proven gold standard drug for preventing restenosis of treated arteries, to the vessel wall during balloon angioplasty without the need for a coating or permanent implant
  • Supported by strong clinical data from the European multi-center prospective clinical trial, SABRE, out to 3 years
  • Virtue SAB is the first angioplasty system that simultaneously delivers sirolimus without any balloon surface coating
  • Along with coronary ISR, Virtue® SAB may have significant follow-on clinical indications such as treatment of coronary small vessels and below-the-knee peripheral artery disease
Have a question?
Contact us at 917.254.4900 or